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Abstract
Background: Metastasis accounts for 90% of cancer-associated mortality in patients with renal cell
carcinoma (RCC). However, the clinical management of RCC metastasis is challenging. Lactate export is
known to play an important role in cancer cell migration. This study investigated the role of heat shock
protein A12A (HSPA12A) in RCC migration.
Methods: HSPA12A expression was examined in 82 pairs of matched RCC tumors and corresponding
normal kidney tissues from patients by immunoblotting and immunofluorescence analyses. The
proliferation of RCC cells was analyzed using MTT and EdU incorporation assays. The migration of RCC
cells was evaluated by wound healing and Transwell migration assays. Extracellular acidification was
examined using Seahorse technology. Protein stability was determined following treatment with protein
synthesis inhibitor cycloheximide and proteasome inhibitor MG132. Mass spectrometry,
immunoprecipitation, and immunoblotting were employed to examine protein-protein interactions.
Results: RCC tumors from patients showed downregulation of HSPA12A, which was associated with
advanced tumor node metastasis stage. Intriguingly, overexpression of HSPA12A in RCC cells inhibited
migration, whereas HSPA12A knockdown had the opposite effect. Lactate export, glycolysis rate, and
CD147 protein abundance were also inhibited by HSPA12A overexpression but promoted by HSPA12A
knockdown. An interaction of HSPA12A with HRD1 ubiquitin E3 ligase was detected in RCC cells.
Further studies demonstrated that CD147 ubiquitination and proteasomal degradation were promoted
by HSPA12A overexpression whereas inhibited by HSPA12A knockdown. Notably, the HSPA12A
overexpression-induced inhibition of lactate export and migration were abolished by CD147
overexpression.
Conclusion: Human RCC shows downregulation of HSPA12A. Overexpression of HSPA12A in RCC
cells unstabilizes CD147 through increasing its ubiquitin-proteasome degradation, thereby inhibits lactate
export and glycolysis, and ultimately suppresses RCC cell migration. Our results demonstrate that
overexpression of HSPA12A might represent a viable strategy for managing RCC metastasis.
Key words: renal cell carcinoma, heat shock protein A12A (HSPA12A), migration, cluster of differentiation 147
(CD147), lactate

Introduction
Renal cell carcinoma (RCC) is one of the most
frequently diagnosed cancers worldwide, and the
incidence rates have been steadily increasing [1-3].

More than 10 histological and molecular subtypes of
RCC have been identified, among which clear cell
RCC (ccRCC) is the most common type and
http://www.thno.org
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accounting for 80% of all cases [2, 4]. The prognosis of
RCC is poor because approximately 25% of patients
present with metastases at the time of diagnosis, and
another 30–35% of patients underwent resection for
localized or locally invasive kidney cancer will
develop potentially fatal metachronous distant
metastases [5, 6]. Therefore, a comprehensive
understanding of RCC metastasis is urgently needed
to develop effective targeted therapies for reducing
the risk of recurrence and death from metastatic
disease.
Cancer cell invasion and metastasis are complex
processes that involve many genetic alterations and
subsequent metabolic transitions [7]. Cluster of
differentiation 147 (CD147) has been shown to play a
critical role in metastasis [8, 9]. CD147, also known as
Basigin or extracellular matrix metalloproteinase
inducer
(EMMPRIN),
is
a
multifunctional
glycoprotein involved in various biological functions
including cell proliferation, survival, and invasion,
and is expressed at high levels in a variety of human
cancers [10-13]. The N-terminal domain of CD147
contains three glycosylation sites, which results in its
molecular mass ranges from 27 kDa for the
non-glycosylated form (NoG-CD147) to 32 kDa for the
low-glycosylated (LG-CD147) form, and 40–65 kDa
for high-glycosylated CD147 (HG-CD147) according
to immunoblot analysis [13, 14]. HG-CD147 is the
mature and active form for facilitating the
translocation of monocarboxylate transporters MCT1
and MCT4 to the membrane [9, 13, 15]. CD147 also
promotes the expression of MCT1 and MCT4 [16, 17].
MCT1 facilitates lactate uptake whereas MCT4 favors
lactate export to increase the content of lactate and
acidification of the tumor microenvironment that
leading to cancer cell migration and invasion [9, 18,
19]. There is convincing evidence that CD147
increases the efficacy of lactate export through MCT4
thereby removing the feedback inhibitory effect of
cellular lactate on glycolytic flux [9, 20]. Thus, CD147
inhibition has been proposed as a potential
therapeutic anti-cancer approach. However, the
regulation of CD147 in cancer cells has not been
clearly clarified.
Heat shock protein A12A (HSPA12A) is a novel
but atypical member of the HSP70 family [21].
Hspa12a mRNA is expressed at high levels in the
human and murine brains under normal conditions,
whereas its expression is decreased in schizophrenia
patients [21, 22]. We recently showed that HSPA12A
mediates a pro-survival pathway against cerebral
ischemic injury, and it also promotes high-fat
diet-induced non-alcoholic liver disease and obesity
[23, 24]. Besides its elevated expression levels in the
brain, HSPA12A is highly expressed in the kidney [23,
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24], suggesting that it might play a role in the
maintenance of renal homeostasis. However, the
involvement of HSPA12A in renal disorders including
renal cancers remains to be investigated.
In this study, we found that RCC tumors from
patients showed downregulation of HSPA12A, which
was associated with advanced tumor node metastasis
(TNM) stage and Fuhrman grade. In loss- and gain-offunction experiments, HSPA12A overexpression
inhibited RCC cell migration whereas HSPA12A
knockdown had the opposite effect. Molecular studies
revealed that HSPA12A decreased CD147 protein
stability
by
promoting
ubiquitin-proteasomal
degradation, thereby inhibited lactate and glycolysis,
and ultimately suppressed RCC cell migration. These
findings suggest that HSPA12A is a novel suppressor
of RCC migration. Thus, HSPA12A overexpression
might represent a viable strategy for preventing
metastasis in human RCC.

Methods
Reagents
Modified McCoy’s 5A medium and MTT [3-(4,
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] reagent were from Sigma-Aldrich (St. Louis,
MO). Trizol reagent and Lipofectamine 3000 were
from Life Technology (Carlsbad, CA). Bovine serum
albumin (BSA) was from Roche (Basel, Switzerland).
Normal Goat Serum was from Jackson ImmunoResearch (West Grove, PA). RPMI 1640 medium and
fetal bovine serum (FBS) were from Biological
Industries (Kibbutz Beit Haemek, ISRAEL). High-sig
ECL western blotting substrate was from Tanon
(Shanghai, China). Protein A-Agarose was from Santa
Cruz Biotechnology (Dallas, TX). Cell-LightTM EdU
Apollo®567 In Vitro Imaging Kit was from RiboBio
(Guangzhou, China). Lactate assay kit was from
Jiancheng Biotech (Nanjing, China). MG132,
cycloheximide (CHX) and SU6656 were from
MedChem Express (Monmouth Junction, NJ).

Human samples
A total of 82 primary RCC tumor samples were
collected from patients who had underwent
nephrectomy in the First Affiliated Hospital of
Nanjing Medical University (Nanjing, China). All
patients were not previously received systemic
therapy. Tumor stage and grade were determined
after nephrectomy according to the 2010 TNM
classification system and the Fuhrman grading system
[25, 26]. In the present study, we included 72 of
clear-cell RCCs, 3 of papillary RCCs, and 1 of
chromophobe RCCs, 2 of spindle cell carcinoma, and
4 other types of carcinoma. The Ethical Board of First
Affiliated Hospital of Nanjing Medical University
http://www.thno.org
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approved these studies (#2019-SR-489). Patients gave
informed consent at the time of recruitment. All the
human studies were conducted according to the
principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human
Services Belmont Report.

Bioinformatics analysis
Using the TCGA (https://www.cancer.gov/
tcga) database, we obtained the standardized
expression levels of HSPA12A mRNA in Kidney renal
clear cell carcinoma and their association with clinical
features, including TNM stage, tumor grade, overall
survival and disease free survival.

Recombinant vectors
The adenoviral vector containing 3 Flags-tagged
coding region of Hspa12a was generated by GeneChem (Shanghai, China) as described in our previous
studies [23, 24]. The pTT3 plasmids containing Cd147
expression coding region (pTT3-CD147) were
provided by Addgene (#36147, Cambridge, MA) [27].

Cell cultures and treatments
Human clear cell carcinoma Caki-1 cells and
human renal cell adenocarcinoma 786O cells were
grown in modified McCoy’s 5A medium and in RPMI
1640 medium, respectively. Both media were
supplemented with 10% fetal bovine serum, 100
units/ml penicillin, and 100 µg/ml streptomycin. All
cell lines were free of mycoplasma contamination.
Cells were plated in 60-mm dishes at a density of
3×105 cells/dish or 24-well plate at a density of 1.5×104
cells/well. The cells were passaged when they
reached at 80% confluence.
Overexpression of HSPA12A in cells was
established by infection with Flag-tagged HSPA12Aexpressing recombinant adenovirus (Ad-HSPA12A)
or normal control vectors (Ad-NC). To overexpress
CD147, cells were transfected with pTT3-CD147
plasmids or empty pTT3 control vectors using
Lipofectamine 3000. Knockdown of HSPA12A was
achieved by introducing HSPA12A-targeting siRNA
(Si-HSPA12A) or the corresponding scramble
negative controls (Si-NC) using siRNA-mate
(Genepharma, China). The siRNA sequences were
shown in Table S1. All the measurements were
performed 48 h after gene overexpression or
knockdown unless indicated elsewhere. In FAK
inhibition experiments, cells were treated with
SU6656 (2µM) 1 h prior to HSPA12A knockdown.

Immunoblotting and
immunoprecipitation-immunoblotting
Tissues or cells were subjected to cytosolic and
nuclear protein preparation using the lysis buffer A
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and B, respectively (Table S2). Equal amount (30 µg)
of proteins was used for immunoblotting according to
our previous methods [23, 24]. To control for lane
loading, the membranes were probed with
anti-GAPDH antibodies for cytosolic proteins and
anti-Lamin A/C antibodies for nuclear proteins. The
developed bands were normalized to the NC control
and expressed as the relative levels.
For analysing interaction between HSPA12A and
CD147 or HRD1 by immunoprecipitation-immunoblotting, Caki-1 or 786O cells were overexpressed
with Flag-tagged HSPA12A. After HSPA12A
overexpression for 48 h, cells were collected for
protein extraction. Aliquots of equal protein content
(0.7 mg) were precipitated with anti-Flag antibodies,
followed by Western blotting with anti-CD147,
anti-HRD1, and anti-HSPA12A antibodies, as
described previously [23].
Antibodies used in the experiments are listed in
Table S3.

Immunofluorescence staining
Immunofluorescence staining was performed on
4% PFA-fixed cells or frozen tissue sections according
to our previous method [23, 24]. Briefly, after
incubation with the indicated primary antibodies (1 :
100) overnight at 4 °C, Cy3- or FITC-conjugated
secondary antibody was applied to the samples to
visualize the staining. Hoechst 33342 reagent was
used to counterstain the nuclei. The staining was
observed using a fluorescence microscope and
quantified using Cellsens Dimention 1.15 software
(Olympus, Tokyo, Japan).

Quantitative real-time PCR
Quantitative real-time PCR was performed as
described previously [23, 24]. Briefly, total RNA was
extracted and an amount of 2 µg of total RNA was
used for cDNA synthesis using the oligo (dT) primer.
After cDNA synthesis, the expressions of indicated
genes were estimated by real-time PCR using the
SYBR Green Master (Roche, Indianapolis, IN). The
PCR results of Gapdh served as internal controls. We
took 2-∆∆CT method in the calculation. The primers
used for PCR were listed in Table S4.

Examination of proliferative ability
MTT assay. After knockdown or overexpression
of HSPA12A for the indicated times, cell viability was
determined using an MTT assay as described
previously [28].

EdU incorporation
Following overexpression of HSPA12A for 46 h,
Caki-1 cells were incubated with EdU for another 2 h.
Cell proliferation was indicated by EdU incorporation
http://www.thno.org
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that visualized by the assay kit according to the
manufacture’s instruction.

in mpH/min, and data were analyzed by Seahorse
XFe24 Wave software.

Examination of migratory ability

Mass spectrometry

Wound healing assay

Human liver carcinoma HepG2 cells with or
without HSPA12A overexpression were used for
mass spectrometry analysis according to previous
study [23]. In brief, the anti-HSPA12A immunoprecipitates were separated by SDS-PAGE followed
by Coomassie-blue staining, digested in gel with
trypsin, and analyzed by liquid chromatographytandem mass spectrometry. Peptides were dissolved
in solvent A (2% FA in 3% ACN) and loaded directly
onto a reversed-phase Trap column (Chrom XP
C18-CL-3m 120A, Eksigent). Peptide separation was
performed using a reversed-phase analytical column
(3C18-CL-120, 3µm, 120A, Eksigent). Eluting peptides
from the column were analyzed using an AB Sciex
5600+ TripleTOF™ system. MS/MS data were
processed using ProteinPilotTM Software 4.5 (AB
Sciex). Tandem mass spectra were searched against
UniProt_Homo sapiens (160,566 sequences, released
on April 9. 2016) database concatenated with reverse
decoy database. Trypsin/P was specified as cleavage
enzyme allowing up to 3 missing cleavages, 4
modifications per peptide and 5 charges.

Following overexpression or knockdown of
HSPA12A for 48 h, cell monolayers that grown in
six-well plates were scratched across the plate to
create a streak wound with a 10 µl pipette tip.
Progression of migration was observed and
photographed at 24 h after wounding and expressed
as the migratory distance using computerized Image J
software (National Institutes of Health, Bethesda,
MD). Three fields on each well were randomly
examined with a magnification of 100.

Transwell migration assay
Cells were plated in the upper chamber of
transwell of 24-well plate (1.5×104 cells/well) following overexpression or knockdown of HSPA12A for 48
h. The pore size of insert was 8 micrometer. After
further culture for another 48 h, the migratory cells
passing through the insert membrane to the lower
chamber were fixed by methanol and stained with 1%
crystal violet. The migrated cells into lower chamber
were quantified in four randomly selected areas at a
magnification of 100 of each sample using Cellsens
Dimention 1.15 software (Olympus, Tokyo, Japan).

Examination of lactate content
Following
HSPA12A
knockdown
or
overexpression for 48 h, culture medium and cells
were collected for lactate content analysis according
to the manufacture’s instruction. In another set of
experiments,
CD147
was
overexpressed
in
Ad-HSPA12A cells for 48 h, and the lactate contents in
culture medium and cells were examined
subsequently. The lactate values were expressed as
relative contents to the respective NC controls.
Also, lactate export was indicated by medium
pH values to indicate acidification.

Measurement of Extracellular acidification
rates (ECAR)
ECAR was examined using a Seahorse XFe24
Extracellular Flux Analyzer (Seahorse Biosciences,
USA). Experiments were performed following
manufacturer's protocols. ECAR was assessed using
Seahorse XF Glycolysis Stress Test Kit. In Brief, 8 × 103
cells per well were seeded into a Seahorse XFe24 cell
culture micro-plate and incubated overnight. Glucose,
the oxidative phosphorylation inhibitor oligomycin,
and the glycolytic inhibitor 2-DG were sequentially
injected into each well at indicated time points
following baseline measurements. ECAR was shown

Flow cytometry
Cells were collected and washed with PBS. After
washing, the cells were stained with anti-human
CD147 APC for 30 min on ice and in dark. The
fluorescence intensity was analyzed by FACSCalibur
(Becton Dickinson). Samples without antibody
incubation or with anti-mouse IgG1 K isotype control
APC served as controls. All of the data were analyzed
with the FlowJo Software (Becton Dickinson).

Statistical analysis
Data represent as mean ± standard deviation
(SD). Groups were compared using Student’s
two-tailed unpaired t-test, Student’s two-tailed paired
t-test, one-way ANOVA or two-way ANOVA
followed by Bonferroni’s test as a post-hoc test. A P
value of < 0.05 was considered as significant.

Results
HSPA12A expression is downregulated in
human RCC
To address the role of HSPA12A in RCC
pathogenesis, we first analyzed Hspa12a mRNA
expression by mining The Cancer Genome Atlas
(TCGA) database for Kidney Renal Clear Cell
Carcinoma (KIRC). The results showed that Hspa12a
mRNA expression was 33.8% lower in human RCC
tissues than in normal controls (Figure 1A).
http://www.thno.org
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Next, we collected 82 pairs of matched RCC
tumors and corresponding normal kidney tissues
from human patients and measured HSPA12A
protein expression, which was downregulated by
28.3% in cytosolic and 37.3% in pellet fractions of RCC
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tumors compared with their normal counterparts
(Figure 1B). Immunofluorescence analysis confirmed
the downregulation of HSPA12A in RCC tumors
(Figure 1C).

Figure 1. Downregulated HSPA12A was associated with the poor prognosis of RCC patients. (A) Hspa12a mRNA levels were obtained from TCGA_KIRC
database. Sample numbers were indicated in figures. TCGA-KIRC, the Cancer Genome Atlas database for Kidney Renal Clear Cell Carcinoma. (B) Human RCC tumors (T) and
the matched non-tumor kidney tissues (N) were collected from surgical patients. Cytosolic and nuclear protein extracts were prepared for immunoblotting. n = 82/group. (C)
Immunofluorescence staining of HSPA12A was performed on frozen sections of RCC tumors and the matched non-tumor kidney tissues of patients. Hoechst 33342 was used
to counterstain the nuclei. Scale bar = 50 µm; n = 3 human subjects/group. (D) Reduced HSPA12A protein expression was associated with advanced TNM stage, Fuhrman grade
and tumor size of human RCC. Sample numbers were indicated in figures. (E) Kaplan-Meier curves indicated the reduced HSPA12A mRNA levels were associated with
shortened survival of KIRC patients in TCGA cohorts from GEPIA website. n = 129 human subjects/group. * P < 0.05, ** P < 0.01.

http://www.thno.org
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HSPA12A downregulation is associated with
unfavorable prognosis in RCC patients
To determine the clinical significance of
HSPA12A downregulation in RCC progression, we
analyzed the association between HSPA12A protein
expression and various clinicopathological variables
in our cohort of 82 RCC patients. Reduced HSPA12A
expression was significantly associated with
advanced TNM stage, high Fuhrman grade, and large
tumor size (Figure 1D). Consistent with our results,
analysis of TCGA cohorts from the UALCAN website
(http://ualcan.path.uab.edu) showed an association
between downregulated Hspa12a mRNA levels and
advanced TNM stage and tumor grade in RCC
patients [29] (Figure S1A-B). Furthermore, the
analysis of the Kaplan-Meier plotter from the GEPIA
database (http://gepia.cancer-pku.cn) indicates a
significant
correlation
of
Hspa12a
mRNA
downregulation with poor overall survival and
disease-free survival in RCC patients [30] (Figure 1E).
Taken together, our findings suggest that HSPA12A
downregulation is associated with poor outcomes in
RCC patients.

Overexpression of HSPA12A reduces
migration but not the proliferation of RCC
cells
The association of HSPA12A downregulation
with poor outcomes in RCC patients led us to
investigate the potential effect of HSPA12A on RCC
cell growth and migration. To this end, HSPA12A was
overexpressed in two different human RCC cell lines
(Caki-1 and 786O) by infection with Flag-tagged
HSPA12A-expressing
recombinant
adenovirus
(Ad-HSPA12A) or normal vector control (Ad-NC).
Knockdown of HSPA12A was achieved by introducing HSPA12A-targeting siRNA (Si-HSPA12A) or
the corresponding scramble control (Si-NC). Neither
HSPA12A overexpression nor its knockdown affected
the viability of Caki-1 and 786O cells compared with
their respective controls (Figure S2A). Also, cell
proliferation was not changed by HSPA12A
overexpression in Caki-1 cells, as indicated by EdU
incorporation (Figure S2B). Consistent with these
results, the mRNA and protein expression of genes
associated with cell survival and proliferation, such as
Bax, Bcl-2, C-Myc, and Cyclin D1, showed no changes
in response to either HSPA12A overexpression or
HSPA12A knockdown in Caki-1 cells (Figure S3A-B).
We then examined whether HSPA12A affects the
migratory ability of RCC cells. The wound closure
assays showed that knockdown of HSPA12A in both
Caki-1 and 786O cells significantly increased cell
migration into the wounds compared with that in
Si-NC controls (Figure 2A). This was also supported
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by the Transwell migration assay results, which
demonstrated a greater number of Caki-1 and 786O
knockdown cells passing through the insert
membranes than Si-NC cells (Figure 2B). By striking
contrast,
HSPA12A
overexpression
markedly
suppressed cell migration for wound closure and the
ability to pass through the Transwell insert
membranes in both Caki-1 and 786O cells (Figure
2A-B). The integrin/FAK/ERKs signaling-mediated
matrix metalloprotease (MMP) expression has been
shown to be critical for cancer metastasis [31-34].
Western blot analysis indicated that HSPA12A
knockdown
promoted,
whereas
HSPA12A
overexpression inhibited integrin-β1, MMP2, and
MMP9 expression in Caki-1 cells compared with their
respective controls (Figure 2C). Also, FAK and ERKs
phosphorylation were promoted by HSPA12A
knockdown whereas inhibited by HSPA12A
overexpression in Caki-1 cells. Similarly, in 786O cells,
overexpression of HSPA12A reduced expression of
integrin-β1 and MMP2 and phosphorylation of FAK
and ERKs compared to their respective NC controls
(Figure S4). Collectively, the data suggest that
HSPA12A negatively regulates RCC cell migration.
To further determine the role of FAK-related
signaling in the migratory regulation of HSPA12A, we
treated Si-HSPA12A and Si-NC Caki-1 cells with
SU6656, a widely used FAK inhibitor that suppresses
FAK phosphorylation [35, 36]. Both wound healing
and Transwell migration assays demonstrated that
SU6656 abolished the HSPA12A knockdown-induced
increase of migration (Figure S5A-C). Moreover, no
difference in cell migration between Si-NC and
Si-HSPA12A groups was observed in the presence of
SU6656. The data suggest that FAK signaling is
involved in the HSPA12A knockdown-induced
promotion of RCC cell migration.

Overexpression of HSPA12A inhibits lactate
export and glycolysis in RCC cells
Lactate, once considered a waste product of
glycolysis, has emerged as a critical regulator of
cancer development, maintenance, and metastasis
[37-40]. We found that the extracellular lactate content
and medium acidification of Caki-1 cells were
increased by HSPA12A knockdown compared with
those of Si-NC controls (Figure 3A-B). By contrast,
HSPA12A overexpression decreased extracellular
lactate content and medium acidification compared
with those in Ad-NC controls (Figure 3A-B). To
exclude the possibility that this change of extracellular
lactate was due to the augmented lactate generation
and therefore increased lactate output, we measured
the intracellular lactate content. The results showed
that the intracellular lactate contents were decreased
http://www.thno.org
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by HSPA12A knockdown but increased by HSPA12A
overexpression in Caki-1 cells compared with the
controls (Figure 3C). Similar effects of HSPA12A on
medium acidification, lactate export, and intracellular
lactate content were observed in 786O cells (Figure
4A-C). Our findings were supported by previous
reports that intracellular lactate accumulation serves
as a negative feedback signal for glycolysis [9, 20].
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To further analyze the effect of HSPA12A on
RCC glycolysis, extracellular acidification rates
(ECAR) were examined using Seahorse technology. A
significant increase in glycolysis rate and capacity was
detected in HSPA12A knockdown Caki-1 cells
compared to the controls (Figure 3D). Consistent with
these observations, knockdown of HSPA12A in
Caki-1 cells upregulated the expression of genes

Figure 2. HSPA12A negatively regulated migration of RCC cells. (A) The wound was made in layers of Caki-1 and 786O cells after overexpression or knockdown of
HSPA12A for 48 h. Following recovery for 24 h, the wound healing was examined and expressed as migration distance (µm). n = 3/group. (B) The extent of cell migration was
assessed in Caki-1 and 786O cells after overexpression or knockdown of HSPA12A for 48 h by Transwell migration assay. The migrated cells stained with crystal violet were
observed 48 h later. n = 3/group. (C) Immunoblotting was performed in Caki-1 cells following overexpression or knockdown of HSPA12A for 48 h. n = 4/group. * P < 0.05, **
P < 0.01. Si-NC, cells transfected with Scramble siRNA; Si-HSPA12A, cells transfected with HSPA12A-targeted siRNA; Ad-NC, cells infected with empty adenovirus;
Ad-HSPA12A, cells infected with HSPA12A-adenovirus.

http://www.thno.org
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regulating glucose uptake (GLUT1 and GLUT4),
glycolysis (HK2 and PFKFB3) and lactate export
(MCT4) (Figure 3E). By contrast, overexpression of
HSPA12A in Caki-1 cells downregulated the
expression of GLUT1, GLUT4, HK2, PFKFB3 and
MCT4 in Caki-1 cells compared to their Ad-NC
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controls. Similarly, the expression of GLUT1, GLUT4,
HK2,
PFKFB3,
LDHA,
and
MCT4
were
downregulated in 786O cells following HSPA12A
overexpression (Figure 4D). These data suggest that
HSPA12A negatively regulates lactate export and
glycolysis of RCC cells.

Figure 3. HSPA12A negatively regulated lactate output and glycolysis of Caki-1 cells. (A) Medium pH values were measured in Caki-1 cultures after knockdown or
overexpression of HSPA12A for 48 h. n = 4/group. (B) Extracellular (medium) lactate contents were examined in Caki-1 cultures after knockdown or overexpression of
HSPA12A for 48 h. n = 4-8/group. (C) Intracellular lactate contents were examined in Caki-1 cells after knockdown or overexpression of HSPA12A for 48 h. n = 4/group. (D)
Extracellular acidification rate of Caki-1 cells was detected after HSPA12A knockdown for 48 h using the Seahorse extracellular flux analyzer. Glycolysis rate represents
extracellular acidification rate after glucose treatment. Glycolysis capacity represents extracellular acidification rate after oligomycin treatment. n = 4/group. (E) Immunoblotting
was performed in Caki-1 cells following knockdown or overexpression of HSPA12A for 48 h. n = 4-7/group. * P < 0.05, ** P < 0.01. Si-NC, cells transfected with Scramble siRNA;
Si-HSPA12A, cells transfected with HSPA12A-targeted siRNA; Ad-NC, cells infected with empty adenovirus; Ad-HSPA12A, cells infected with HSPA12A-adenovirus.
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Figure 4. Downregulation of HSPA12A promoted lactate export and glycolysis of 786O cells. (A) pH values in medium of 786O cells were measured following
knockdown or overexpression of HSPA12A for 48 h. n = 4/group. (B) Extracellular (medium) lactate contents were examined in 786O cultures after knockdown or
overexpression of HSPA12A for 48 h. n = 8/group (upper panel) and n = 4/group (down panel). (C) Intracellular lactate contents were examined in 786O cells after knockdown
or overexpression of HSPA12A for 48 h. n = 4/group except for n = 3 in Si-HSPA12A group. (D) Immunoblotting was performed in 786O cells following overexpression of
HSPA12A for 48 h. n = 3/group. * P < 0.05, ** P < 0.01. Si-NC, cells transfected with Scramble siRNA; Si-HSPA12A, cells transfected with HSPA12A-targeted siRNA; Ad-NC, cells
infected with empty adenovirus; Ad-HSPA12A, cells infected with HSPA12A-adenovirus.

Overexpression of HSPA12A decreases
CD147 protein abundance, maturation, and
membrane localization
The transmembrane glycoprotein CD147 has
been shown to promote migration and glycolysis of
cancer cells via MCT4-mediated lactate export [9, 15,
27, 41-43]. Based on our previous unbiased screen
with mass-spectrometric analysis, showing an
interaction between HSPA12A and CD147 in human
hepatocellular carcinoma cells (Figure S6), we
hypothesized that HSPA12A might play a role in the
regulation of CD147 during RCC migration.
Nonetheless, CD147 protein was not detected in the
HSPA12A immunocomplexes of Caki-1 and 786O
cells (Figure S7A-B), suggesting the lack of direct

interaction between HSPA12A and CD147 in RCC
cells.
However,
both
immunoblotting
and
immunostaining analyses revealed increased CD147
protein expression accompanied by reduced
HSPA12A expression in human RCC tumors
compared to their normal counterparts (Figure 5A-B),
indicating that HSPA12A might negatively regulate
CD147 expression. Indeed, CD147 protein levels were
increased by HSPA12A knockdown but decreased by
HSPA12A overexpression in Caki-1 cells as indicated
by both immunoblotting and immunostaining
analyses (Figure 5C-D). Reduced CD147 expression
was also observed in HSPA12A-overexpressing 786O
cells compared to NC controls (Figure S8). The effects
of HSPA12A on CD147 expression was also confirmed
by flow cytometry (Figure S9).
http://www.thno.org
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Figure 5. HSPA12A negatively regulated CD147 protein abundance, maturation and membrane localization. (A) Human RCC tumors and the matched
non-tumor kidney tissues were collected for immunoblotting. n = 40/group. (B) Human RCC tumors and the matched non-tumor kidney tissues were prepared for
immunofluorescence staining of CD147 and HSPA12A. Hoechst 33342 was used to counterstain the nuclei. Scale bar = 50 µm. n = 3 human subjects/group. (C,D)
Immunoblotting was performed in Caki-1 cells following knockdown (C) or overexpression (D) of HSPA12A for 48 h. n = 4-8/group. (E,F) Immunofluorescence staining against
CD147 was performed in Caki-1 cells following knockdown (E) or overexpression (F) of HSPA12A for 48 h. Hoechst 33342 was used to counterstain the nuclei. Scale bar = 50
µm. n = 3/group. * P < 0.05, ** P < 0.01. Si-NC, cells transfected with Scramble siRNA; Si-HSPA12A, cells transfected with HSPA12A-targeted siRNA; Ad-NC, cells infected with
empty adenovirus; Ad-HSPA12A, cells infected with HSPA12A-adenovirus; HG-CD147, high-glycosylation CD147; LG-CD147, low-glycosylation CD147.

High glycosylation is an indicator of CD147
maturation for its membrane localization [13].
Interestingly, HG-CD147 levels were increased in
human RCC tumors accompanied by reduced
HSPA12A expression (Figure 5A). Moreover,
HSPA12A knockdown increased, whereas HSPA12A
overexpression decreased HG-CD147 content in

Caki-1 cells (Figure 5C-D). HSPA12A knockdown
also
substantially
increased
the
membrane
localization of CD147 in Caki-1 cells, whereas
HSPA12A overexpression markedly decreased CD147
membrane localization (Figure 5E-F). Besides, a
decreased HG-CD147 protein content was observed in
786O cells following HSPA12A overexpression
http://www.thno.org
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(Figure S8). These findings collectively indicate that
HSPA12A negatively regulates CD147 protein
abundance, maturation, and membrane localization in
RCC cells.
Given that CD147 promotes lactate export by
promoting MCT4 stability, cell surface expression,
and function [15, 42, 43], we analyzed the effect of
HSPA12A on MCT4 expression. We found that
human RCC tumors with lower HSPA12A expression
showed significantly higher MCT4 protein expression
than their corresponding non-tumor counterparts
(Figure S10A-B). This observation was confirmed by
in vitro experiments showing that HSPA12A knockdown increased, whereas HSPA12A overexpression
decreased MCT4 protein expression in both Caki-1
and 786O cells compared with control cells (Figure 3E
and 4D). However, neither HSPA12A knockdown nor
HSPA12A overexpression affected Mct4 mRNA levels
in Caki-1 cells (Figure S11), indicating that HSPA12A
may regulate MCT4 at post-transcriptional levels.

Overexpression of HSPA12A reduces CD147
to mediate anti-migration effects
To determine whether the anti-migratory
activity of HSPA12A overexpression is mediated by
decreasing CD147, we overexpressed CD147 in
HSPA12A
overexpressing-Caki-1
cells
(Ad-HSPA12A) by transfection with pTT3-CD147
plasmid or empty pTT3 vector control (Figure 6A-B).
Notably, overexpression of CD147 reversed the
HSPA12A-induced inhibition of cell migration in the
Transwell migration assay (Figure 6C). Consistent
with this observation, overexpression of CD147 in
Ad-HSPA12A Caki-1 cells upregulated integrin-β1,
MMP2, MMP7, and MMP9 protein expression and
increased FAK phosphorylation compared to pTT3
controls (Figure 6D). Similar results were observed in
786O cells showing that overexpression of CD147
reversed the HSPA12A-induced inhibition of cell
migration in the Transwell migration assay (Figure
S12) and also increased FAK phosphorylation
compared to pTT3 controls (Figure S13). These data
indicate that HSPA12A inhibits RCC cell migration by
reducing CD147.

Overexpression of HSPA12A reduces CD147
to mediate anti-lactate export and
anti-glycolysis effects
We next investigated whether the HSPA12Ainduced inhibition of lactate export and glycolysis
were mediated by the reduction of CD147. We noted
that overexpression of CD147 in Ad-HSPA12A Caki-1
and 786O cells increased medium acidification
compared with control (pTT3) cells (Figures 7A).
Consistently, lactate content was increased
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extracellularly (culture medium) and decreased
intracellularly in Ad-HSPA12A Caki-1 and 786O cells
following CD147 overexpression (Figures 7B). Also,
overexpression of CD147 in Ad-HSPA12A cells
upregulated protein expression of the genes involved
in glucose uptake (GLUT1 and GLUT4), glycolysis
(HK2, PFKFB3 and LDHA), and lactate export (MCT4)
(Figure 7C), compared to their pTT3 controls. These
results indicate that HSPA12A inhibits lactate export
and glycolysis by reducing CD147 protein expression.

HSPA12A reduces CD147 protein stability via
ubiquitin-proteasome degradation
Next, we explored the potential mechanisms
underlying the HSPA12A-mediated regulation of
CD147 protein expression. Unexpectedly, neither
HSPA12A knockdown nor HSPA12A overexpression
had an effect on Cd147 mRNA levels in Caki-1 and
786O cells that were comparable to the respective NC
controls (Figures 8A and S14). Analysis of the TCGA
database for KIRC showed comparable Cd147 mRNA
levels between RCC tumors and their normal controls
(Figure S15), supporting our observations and
suggesting that HSPA12A may regulate CD147
protein stability. To test this hypothesis, we treated
Si-HSPA12A Caki-1 cells with cycloheximide (CHX)
to block protein translation for 48 and 72 h. Notably,
the remaining HG-CD147 protein content, which was
expressed as the percentage over NC level at 0 h, was
significantly higher in Si-HSPA12A Caki-1 cells than
in Si-NC cells after treatment with CHX up to 72 h
(Figure 8B). Similar results were detected in 786O
cells following CHX treatment (Figure S16). These
data indicate that knockdown of HSPA12A increased
CD147 protein stability.
The proteasome is an important system for
protein degradation [42]. To investigate whether
HSPA12A regulates CD147 protein stability by
modulating its proteasomal degradation, we
examined the effects of the proteasome inhibitor
MG132 on HSPA12A-induced changes in CD147
stability in both Caki-1 and 786O cells. The results
showed that the HSPA12A overexpression-induced
reduction of CD147 was abrogated in the presence of
MG132 (Figures 8C and S17A). Furthermore, CD147
protein level was increased by MG132 in Si-NC
control cells, whereas it was comparable between
MG132 and vehicle groups in HSPA12A knockdown
Caki-1 and 786O cells (Figures 8D and S17B). The
analysis of flow cytometry confirmed that the
HSPA12A-induced decrease of CD147 in Caki-1 cells
was abolished in the presence of MG132 (Figure S9).
Taken together, these results suggest that the
HSPA12A-induced negative regulation of CD147
protein stability is proteasome-dependent.
http://www.thno.org
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Figure 6. Overexpression of CD147 reversed the HSPA12A-induced inhibition of RCC cell migration. Twenty-four hours after HSPA12A overexpression, Caki-1
cells (Ad-HSPA12A) were transfected with pTT3-CD147 plasmids to overexpress CD147 or transfected with pTT3 control plasmids. The following experiments were
performed 48 h after plasmid transfection. (A) Cd147 mRNA levels were examined by real-time PCR. n = 6/group. (B) CD147 protein levels were examined by immunoblotting.
n = 6/group. SE, short exposure; LE, long exposure. (C) The extent of cell migration was assessed by Transwell migration assay. n = 3/group. (D) Immunoblotting against the
indicated proteins was performed. n = 3-4/group. * P < 0.05, ** P < 0.01. Ad-NC, cells infected with empty adenovirus; Ad-HSPA12A, cells infected with HSPA12A-adenovirus;
HG-CD147, high-glycosylation CD147; LG-CD147, low-glycosylation CD147; pTT3, empty pTT3 plasmid; pTT3-CD147, plasmid expressing CD147.

Considering that ubiquitination is necessary for
proteasomal protein degradation, we examined the
effects of HSPA12A on CD147 ubiquitination. To this
end, ubiquitin-conjugated proteins from HSPA12Aoverexpressing (Ad-HSPA12A) Caki-1 cells and the
control (Ad-NC) cells were immunoprecipitated with
the antibody against ubiquitin. The ubiquitinprecipitates from Ad-HSPA12A cells showed higher
HG-CD147 protein content than the precipitates from
Ad-NC cells and a higher level of non-glycosylated
CD147 (NoG-CD147) was recovered rather than
LG-CD147 (Figure 9A). Conversely, HSPA12A
deficiency significantly reduced the ubiquitination of
both HG-CD147 and NoG-CD147 compared with that
in control cells using immunoprecipitation immunoblotting analyses (Figure S18).

HSPA12A interacts with HMG-CoA reductase
degradation protein 1 (HRD1), an E3 ubiquitin
ligase
HRD1 is a ubiquitin E3 ligase that ubiquitinates
and degrades CD147 [44, 45]. To examine whether
HRD1 was involved in the HSPA12A-induced CD147
proteasomal degradation, we first evaluated the
effects of HSPA12A on HRD1 expression. A
significant increase of HRD1 protein expression was
found in both Caki-1 and 786O cells following
HSPA12A overexpression compared to their Ad-NC
controls (Figure 9B). Notably, immunoprecipitationimmunoblotting analysis revealed the presence of
HRD1 protein in the Flag-tagged HSPA12A
immuno-precipitates from Ad-HSPA12A Caki-1 or
786O cells, showing the interaction of HSPA12A with
HRD1 in RCC cells (Figure 9C).
http://www.thno.org
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Figure 7. Overexpression of CD147 diminished the HSPA12A-induced inhibition of lactate output and glycolysis. Twenty-four hours after HSPA12A
overexpression, Caki-1 and 786O cells were transfected with pTT3-CD147 plasmids to overexpress CD147 or transfected with pTT3 control plasmids. The following
experiments were performed 48 h after plasmid transfection. (A) Medium pH values were measured. n = 3-4/group. (B) Lactate contents in both extracellular (medium) and
intracellular fractions were examined. n = 3-7/group. (C) Immunoblotting against the indicated proteins was performed. n = 3-7/group. * P < 0.05, ** P < 0.01. Ad-HSPA12A, cells
infected with HSPA12A-adenovirus; pTT3, empty pTT3 plasmid; pTT3-CD147, plasmid expressing CD147.

Discussion
In this study, we identified HSPA12A as a novel
negative regulator of renal cancer cell migration and
metastasis. HSPA12A’s function, as a potential
migration- and metastasis suppressor, was mediated
by modulating CD147 stability and CD147-mediated
lactate export and glycolysis (Figure 9D). These
findings indicate that promoting HSPA12A
expression could be an effective strategy for the
management of RCC metastasis.

HSPA12A belongs to the evolutionarily
conserved superfamily of HSPs, comprising a group
of structurally unrelated subfamilies, including
HSPA/HSP70, HSPB/HSP27, HSPC/HSP90, HSPH/
HSP110, and NDAJ/HSP40 [46]. Several HSPs,
especially HSP27, HSP72, and HSP90, are upregulated
in a variety of human cancers (e.g. hepatocellular and
prostate carcinomas) to form a fostering environment
essential for tumor growth, invasion, and metastasis,
leading to secondary cancers by chaperoning
http://www.thno.org
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uncontrolled proliferation, angiogenesis, epithelialmesenchymal transition, and escaping cell death and
senescence [47]. In renal cancers, HSP27, HSP72, and
HSP90 show a heterogeneous expression pattern.
However, HSP40 family protein DNAJB8 is
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upregulated in renal cancers and induces
tumorigenesis by maintaining cancer stem-like cells, a
population of cancer cells with tumor initiation,
self-renewal, and differentiation properties [48, 49].

Figure 8. HSPA12A negatively regulated CD147 stability through proteasomal degradation. (A) Levels of Cd147 mRNA were examined in Caki-1 cells following
HSPA12A knockdown or overexpression for 48 h. n = 5-6/group. ns, no significance. (B) Twenty-four hours after HSPA12A knockdown, Caki-1 cells were treated with
cycloheximide (CHX, 150 µg/ml) for the indicated durations. CD147 protein abundance was examined by immunoblotting and expressed as the percentage of the contents at 0
h. n = 3/group. * P < 0.05 vs. the time matched Si-NC group. SE, short exposure; LE, long exposure. (C) Forty-eight hours after HSPA12A overexpression, Caki-1 cells were
treated with MG132 (20 µM) for 8 h. CD147 protein abundance was examined by immunoblotting. n = 6/group. (D) Forty-eight hours after HSPA12A knockdown, Caki-1 cells
were treated with MG132 (20 µM) for 8 h. CD147 protein abundance was examined by immunoblotting. n = 3/group. * P < 0.05. ** P < 0.01. Si-NC, cells transfected with
Scramble siRNA; Si-HSPA12A, cells transfected with HSPA12A-targeted siRNA; Ad-NC, cells infected with empty adenovirus; Ad-HSPA12A, cells infected with
HSPA12A-adenovirus; HG-CD147, high-glycosylation CD147; LG-CD147, low-glycosylation CD147.
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Figure 9. HSPA12A interacted with ubiquitin E3 ligase HRD1 and increased CD147 ubiquitination. (A) Immunoprecipitation with ubiquitin was performed in
Caki-1 cells following overexpression of HSPA12A for 48 h. Immunoblotting for CD147 was performed in ubiquitin immunoprecipitates. Protein extracts without
immunoprecipitation (input) served as positive controls, and immunoprecipitates from IgG incubation served as negative controls. n = 4/group. (B) Immunoblotting was
performed in Caki-1 and 786O cells following overexpression of HSPA12A for 48 h. n = 4/group. (C) Immunoprecipitation with Flag-tagged HSPA12A was performed in Caki-1
and 786O cells following overexpression of HSPA12A for 48 h. Immunoblotting for HRD1 was performed in immunoprecipitates. Protein extracts without immunoprecipitation
(input) served as positive controls, and immunoprecipitates from IgG incubation served as negative controls. n = 3/group. (D) Mechanistic scheme. HSPA12A interacts with E3
ubiquitin ligase HRD1. Overexpression of HSPA12A in RCC cells unstabilizes CD147 through increasing ubiquitin-proteasome degradation, thereby inhibits lactate export and
glycolysis, and ultimately suppresses RCC cell migration. * P < 0.05. ** P < 0.01. Ad-NC, cells infected with empty adenovirus; Ad-HSPA12A, cells infected with
HSPA12A-adenovirus; HG-CD147, high-glycosylation CD147; NoG-CD147, non-glycosylation CD147; HRD1, HMG-CoA reductase degradation protein 1.

In the present study, we detected a
downregulated expression of HSPA12A in human
RCC tumors, which was associated with advanced
TNM stage and Fuhrman grade, as well as larger
tumor size. The Kaplan-Meier plotter from the GEPIA

database showed a correlation between low Hspa12a
mRNA expression and poor survival in RCC patients.
Loss- and gain-of HSPA12A function experiments in
human RCC cells showed that HSPA12A did not
directly regulate RCC cell proliferation but exhibited a
http://www.thno.org
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negative correlation with RCC cell migration. We also
found
that
HSPA12A
negatively
regulated
phosphorylation of FAK as well as the expression of
integrin-β1 and MMP2/9. FAK is a multifunctional
regulator of cell signaling within the tumor
microenvironment and is at the intersection of various
signaling pathways that promote cancer metastasis. It
can be activated by integrin-β to increase the
expression or activation of MMPs, which, in turn,
facilitate tumor cell invasion into the surrounding
microenvironment [31-33]. Various other tumorpromoting signaling pathways are also involved in
FAK’s function. Thus, FAK inhibitors are emerging as
promising chemotherapeutics for tumor metastasis in
mouse models. In our study, inhibition of FAK
diminished the HSPA12A knockdown-induced
promotion of RCC cell migration, suggesting that
FAK signaling was involved in the regulation of
HSPA12A in RCC migration. These findings suggest
that the downregulation of HSPA12A expression was
associated with poor prognosis in human RCC, which
could be attributed to the negative regulatory effect of
HSPA12A on RCC cell migration. The results
provided insights into the role of heat shock proteins
in cancer progression.
CD147 is a glycoprotein that was initially
identified as a regulator of MMPs. Increasing
evidence indicates that CD147 is overexpressed in
cancer cells and involved in promoting cancer cell
metastasis through several mechanisms. One
important mechanism underlying the effect of CD147
on promoting cancer metastasis is the metabolic
modification of the tumor microenvironment through
interactions with specific MCTs, such as MCT4, to
facilitate lactate export and tumor glycolysis [37, 50].
Moreover, CD147 induces MMPs expression by
activating FAK in an integrin-dependent manner [50].
However, little is known about the regulation of heat
shock proteins in CD147 expression. Here, we found
that human RCC tumors showed reduced HSPA12A
accompanied by increased CD147 protein expression,
suggesting that downregulation of HSPA12A might
increase RCC cell migration by upregulating CD147.
This hypothesis was supported by the findings that
HSPA12A negatively regulated CD147 protein
abundance and membrane expression in RCC cells.
Moreover, HSPA12A negatively regulated lactate
export, which was not caused by changes in lactate
generation. In view of previous reports showing that
intracellular lactate accumulation serves as a negative
feedback signal for glycolysis [9, 20], the present data
suggest that the downregulation of HSPA12A might
increase lactate export to upregulate glycolysis.
Indeed, the glycolysis rate, glycolytic capacity and
expression of glycolysis-related genes were promoted
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by HSPA12A knockdown in RCC cells. More
importantly, overexpression of CD147 reversed the
HSPA12A overexpression-induced inhibition of RCC
cell migration, lactate export, and the glycolysisrelated gene expression. These data suggest that the
downregulation of HSPA12A in RCC cells increases
migration and glycolysis in a CD147-dependent
manner.
Previous studies have reported that CD147 can
promote the proliferation of some cancer cells such as
hepatocellular carcinoma cells
through
multiple
pathways such as PI3K/Akt signaling [51, 52].
Though we found a negative regulation of HSPA12A
in CD147 protein abundance, the proliferation of both
Caki-1 and 786O RCC cells was not affected by
knockdown or overexpression of HSPA12A. The Akt
activation in RCC cells was also not affected by
HSPA12A (Figure S19). When taken into account that
our recent reports have shown a promoted
proliferation of hepatocellular carcinoma cells by
HSPA12A [53], the current data suggest that the
effects of CD147 and HSPA12A on proliferation are
cancer cell type- and signaling activation-dependent.
Evidence has shown that CD147 is degraded
through the ubiquitin-proteasome system, and HRD1
is an E3 ligase involved in CD147 ubiquitination [54].
Previous studies have demonstrated that HRD1 is an
endoplasmic reticulum–associated ubiquitin ligase
involved in CD147 degradation in human
hepatocellular carcinoma cells. Moreover, HRD1 has
been shown to form a signaling axis with HSP70 to
regulate the onco-repressor potential of N-terminal
misfolded Blimp-1s in lymphoma cells [55]. To
understand the increased CD147 protein expression
by downregulated HSPA12A, we analyzed its effect
on Cd147 mRNA levels and found that HSPA12A did
not affect Cd147 mRNA expression in RCC cells. Our
results were supported by the TCGA database which
showed a comparable Cd147 mRNA expression
between RCC patients and the normal controls. We
speculated that HSPA12A might regulate CD147
protein abundance by modulating its stability. The
following findings supported this hypothesis. (1)
Protein synthesis blocker CHX caused a gradual
decrease in CD147 protein abundance in control RCC
cells; however, the CHX-induced reduction of CD147
protein abundance was attenuated by HSPA12A
knockdown, (2) Treatment with the proteasome
inhibitor
MG132
abolished
the
HSPA12A
overexpression-induced decrease of CD147 protein,
(3) In the ubiquitin immuno-precipitates from
HSPA12A-overexpressing RCC cells, CD147 was
present at a higher level, and the opposite pattern was
observed in response to HSPA12A knockdown, and
(4) HSPA12A showed an interaction with E3 ubiquitin
http://www.thno.org
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ligase HRD1. These results suggest that HSPA12A
negatively regulates CD147 protein stability by
modulating CD147 ubiquitination for proteasomal
degradation.

Conclusion
Our study demonstrated that the loss of
HSPA12A was associated with metastasis in human
RCC, while overexpression of HSPA12A inhibited
RCC cell migration. We further provided evidence
that the anti-metastatic action of HSPA12A was
caused by the negative regulation of CD147 stability
and the CD147-mediated lactate export (Figure 9D).
The present data suggest that increasing HSPA12A
expression provides an effective strategy for
preventing migration of human RCC cells.
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